



State of California—Health and Human Services Agency  
Department of Health Care Services



EDMUND G. BROWN JR.  
GOVERNOR

May 9, 2016

CHDP Provider Information Notice No.: 16-01

TO: ALL CHILD HEALTH AND DISABILITY PREVENTION (CHDP)  
PROGRAM PROVIDERS AND MEDI-CAL MANAGED CARE PLANS

SUBJECT: MENINGOCOCCAL B VACCINES CPT CODES 90620 (BEXSERO®)  
AND 90621 (TRUMENBA®): NEW CHDP PROGRAM VACCINES FOR  
CHILDREN AND YOUTH (VFC) BENEFITS: NEW VACCINE  
PROCEDURE CODES FOR VFC VACCINE ADMINISTRATION AND  
FOR NON VFC VACCINE ADMINISTRATION

The purpose of this Provider Information Notice (PIN) is to inform providers about the addition of two new CHDP Program Meningococcal serogroup B (Men B) vaccines and the following new additional Program Procedure Codes, outlined in the table below, for meningococcal recombinant protein and outer membrane vesicle vaccine, Bexsero®, CPT Code 90620 (2-dose schedule) and meningococcal recombinant lipoprotein vaccine, Trumenba®, CPT Code 90621 (3-dose schedule).\*

**\* PLEASE NOTE NEW ALPHA NUMERIC CHDP PROGRAM SERVICE CODES**

Medi-Cal Code	Medi-Cal Description	Age Group	CHDP Code	CHDP Description	Reimbursement
90620	Bexsero®	10 years through 18 years 11 months*	M1	VFC	\$9
90620	Bexsero®	19 years through 20 years 11 months*	M2 + M3	Non VFC	\$168.36
90621	Trumenba®	10 years through 18 years 11 months*	M4	VFC	\$9
90621	Trumenba®	19 years through 20 years 11 months*	M5 + M6	Non VFC	\$123.54

\*Persons at increased risk for meningococcal disease including:

- For purposes of the CHDP program children and youth aged 10 through 20 years 11 months, are at increased risk for meningococcal disease attributable to Serogroup B, including:
  - Individuals who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor D, factor H, or who are taking eculizumab (Soliris®).
  - Individuals who have anatomic or functional asplenia, including sickle cell disease.
  - Individuals identified to be at increased risk because of meningococcal disease outbreak attributable to Serogroup B.

In addition, youth aged 16 through 18 years, without high risk conditions, may also be vaccinated.

**Background:**

In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.]) as a 3-dose series. In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series. Both vaccines were approved for use in persons aged 10–25 years. Please refer to Weekly MMWR [Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015](#). Please also refer to the Medi-Cal Update General Medicine –July section 3. Meningococcal B Vaccines: New Medi-Cal and VFC Benefits: <http://files.medi-cal.ca.gov/pubsdoco/bulletins/artfull/gm201507.asp> and the [VFC Letter for Bexero® and Trumenba®](#)

Effective date October 1, 2015.

Bexsero®: Code is M1 for VFC administration fee, 10 years through 18 years 11 months.

Bexsero®: Code is M2 + M3 for Non VFC (has two dose schedule, at least one month apart): 19 years through 20 years 11 months. There are two shots in the series with a minimum of a 30 day series interval between the first and second shot.

Trumenba®: Code M4 for VFC administration fee, 10 years through 18 years 11 months.

May 9, 2016

Trumenba®: Code M5 + M6 for Non VFC (has three dose schedule, 0, 2, and 6 month schedule): 19 years through 20 years 11 months. There are 3 shots in the series with a minimum of a 60 day series interval between the first and second shots and a minimum of 180 day series interval between the second and third shots.

Either Trumenba® or Bexsero® should be administered but not given together. Your continuing participation in the CHDP Program is greatly appreciated. If you have any questions, please contact your local CHDP program.

Sincerely,

**ORIGINAL SIGNED BY PATRICIA MCCLELLAND**

Patricia McClelland, Chief  
Systems of Care Division